ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024 at 07:00 AM EST
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.